Global PD-1 Antibody Drug Market Growth 2023-2029

Global PD-1 Antibody Drug Market Growth 2023-2029

The global PD-1 Antibody Drug market size is projected to grow from US$ 32280 million in 2022 to US$ 85010 million in 2029; it is expected to grow at a CAGR of 14.8% from 2023 to 2029.

United States market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key PD-1 Antibody Drug players cover Novartis, Thermo Fisher, InvivoGen, BioVision Inc., Abcam, Bristol-Myers Squibb, Merck, Ono Pharmaceutical Co., Ltd and Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

PD-1 is an immune checkpoint inhibitor, which is relatively widely used clinically

LPI (LP Information)' newest research report, the “PD-1 Antibody Drug Industry Forecast” looks at past sales and reviews total world PD-1 Antibody Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected PD-1 Antibody Drug sales for 2023 through 2029. With PD-1 Antibody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 Antibody Drug industry.

This Insight Report provides a comprehensive analysis of the global PD-1 Antibody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 Antibody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PD-1 Antibody Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 Antibody Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 Antibody Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 Antibody Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Pembrolizumab
Nivolumab
Sindilimab
Toripalimab
Other

Segmentation by application
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Thermo Fisher
InvivoGen
BioVision Inc.
Abcam
Bristol-Myers Squibb
Merck
Ono Pharmaceutical Co., Ltd
Eli Lilly
Chugai Pharmaceutical Co., Ltd
BeiGene
AbbVie
TG Therapeutics, Inc
Beijing Yiqiao Shenzhou Technology Co., Ltd.
3SBio

Key Questions Addressed in this Report

What is the 10-year outlook for the global PD-1 Antibody Drug market?

What factors are driving PD-1 Antibody Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PD-1 Antibody Drug market opportunities vary by end market size?

How does PD-1 Antibody Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.